244 related articles for article (PubMed ID: 6502914)
1. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
Ichikawa S; Tajima Y; Sakamaki T; Matsuo H; Kogure M; Hirano Y; Yagi S; Murata K
Jpn Circ J; 1984 Nov; 48(11):1184-96. PubMed ID: 6502914
[TBL] [Abstract][Full Text] [Related]
2. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
3. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism.
Sakamoto H; Ichikawa S; Sakamaki T; Nakamura T; Ono Z; Takayama Y; Murata K
Am J Hypertens; 1990 Jul; 3(7):533-7. PubMed ID: 2194510
[TBL] [Abstract][Full Text] [Related]
4. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
Rossi E; Sani C; Perazzoli F; Casoli MC; Negro A; Dotti C
Am J Hypertens; 1995 Sep; 8(9):884-93. PubMed ID: 8541003
[TBL] [Abstract][Full Text] [Related]
5. Plasma renin activity in the diagnosis of primary aldosteronism: failure to distinguish primary aldosteronism from essential hypertension.
Jose A; Kaplan NM
Arch Intern Med; 1969 Feb; 123(2):141-6. PubMed ID: 5812600
[No Abstract] [Full Text] [Related]
6. Spironolactone prevents Na+/H+ exchange enhancement in primary aldosteronism.
Koren W; Koldanov R; Postnov IY; Postnov YV
Am J Hypertens; 1997 Mar; 10(3):341-5. PubMed ID: 9056693
[TBL] [Abstract][Full Text] [Related]
7. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
Brown JJ; Davies DL; Ferriss JB; Fraser R; Haywood E; Lever AF; Robertson JI
Br Med J; 1972 Jun; 2(5816):729-34. PubMed ID: 4338668
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone as a nonspecific treatment for primary aldosteronism.
Bravo EL; Dustan HP; Tarazi RC
Circulation; 1973 Sep; 48(3):491-8. PubMed ID: 4726231
[No Abstract] [Full Text] [Related]
9. Effect of spironolactone on urinary excretion of immunoreactive prostaglandin E in essential hypertension and primary aldosteronism.
Chiba S; Abe K; Yasujima M; Irokawa N; Seino M; Sakurai Y; Sato M; Otsuka Y; Yoshinaga K
Tohoku J Exp Med; 1978 Apr; 124(4):297-305. PubMed ID: 663929
[TBL] [Abstract][Full Text] [Related]
10. Volume-pressure relationships during development of mineralocorticoid hypertension in man.
Wenting GH; Man in 't Veld AJ; Verhoeven RP; Derkx FH; Schalekamp DH
Circ Res; 1977 May; 40(5 Suppl 1):I163-70. PubMed ID: 858175
[TBL] [Abstract][Full Text] [Related]
11. Studies on essential hypertension with suppressed plasma renin activity: sodium excretion pattern on salt restriction and effects of spironolactone on blood pressure and plasma renin activity.
Uchida K; Morimoto S; Takeda R; Murakami M
Jpn Circ J; 1972 Dec; 36(12):1301-11. PubMed ID: 4679217
[No Abstract] [Full Text] [Related]
12. Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes.
Kremer D; Beevers DG; Brown JJ; Davies DL; Ferriss JB; Fraser R; Lever AF; Robertson JI
Clin Sci Mol Med Suppl; 1973 Aug; 45 Suppl 1():213s-8. PubMed ID: 4361398
[No Abstract] [Full Text] [Related]
13. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.
Loh KC; Koay ES; Khaw MC; Emmanuel SC; Young WF
J Clin Endocrinol Metab; 2000 Aug; 85(8):2854-9. PubMed ID: 10946893
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of hypertension in primary aldosteronism after discontinuation of spironolactone. Time course of changes in cardiac output and body fluid volumes.
Wenting GJ; Man in 't Veld AJ; Derkx FH; Schalekamp MA
Clin Exp Hypertens A; 1982; 4(9-10):1727-48. PubMed ID: 6754151
[TBL] [Abstract][Full Text] [Related]
15. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
[TBL] [Abstract][Full Text] [Related]
16. Role of atrial natriuretic peptide in mineralocorticoid escape phenomenon in patients with primary aldosteronism.
Nakamura T; Ichikawa S; Sakamaki T; Sato K; Kogure M; Tajima Y; Kato T; Murata K
Proc Soc Exp Biol Med; 1987 Sep; 185(4):448-54. PubMed ID: 2956609
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism].
Yokoyama T; Shimamoto K; Iimura O
Nihon Naibunpi Gakkai Zasshi; 1995 Nov; 71(7):1059-74. PubMed ID: 8582487
[TBL] [Abstract][Full Text] [Related]
18. Abnormal relation of extracellular fluid volume and exchangeable sodium with systemic arterial pressure in early borderline essential hypertension.
Lebel M; Grose JH; Blais R
Am J Cardiol; 1984 Dec; 54(10):1267-71. PubMed ID: 6391132
[TBL] [Abstract][Full Text] [Related]
19. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
20. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension.
van Brummelen P; Schalekamp MA
Acta Med Scand; 1980; 207(4):259-64. PubMed ID: 6992515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
